Replimune Group's RP1 oncolytic virus therapy faced an FDA rejection, raising concerns about the platform's viability in ...

One of the most notable accomplishments of the first Trump Administration was its willingness to take on the status quo of ...

As CEO of the psychedelic medicine company Compass Pathways, Kabir Nath has had a front-row seat to a dramatic year in the ...

Avobis Bio LLC, a clinical stage company developing implantable cell therapies, announced today that primary analysis of the ...

Designed to expand PSMA PET imaging access for patients by increasing batch size by ~50% and enhancing supply resilience PDUFA date set for March 6, 2026 BEDFORD, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) ...

The FDA accepted a supplemental application for Breyanzi to treat adults with relapsed or refractory marginal zone lymphoma ...

The biosimilars market represents a transformative segment within the global pharmaceutical industry, offering highly similar ...

Dr. David A. Kessler has outlined a legal path for Health Secretary Robert F. Kennedy Jr. to take on the food industry, while ...

News archive including articles on Fund Managers, Fund Selection, Asset Allocation, Absolute Return, Offshore Investments, Tax Shelters, Insurance bonds. Momentum returns as biotech enters next phase ...

The deal brings the FDA-approved neuroblastoma therapy Danyelza (naxitamab-gqgk) to SERB Pharmaceuticals and advances its ...

Health and Human Services Secretary Robert F. Kennedy Jr. said this week that he's pulling the plug on nearly $500 million in ...

Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” second-quarter 2025 investor letter.